LAB earnings analysis
What we found in LAB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Standard BioTools reported a Q1 2026 revenue of $21.15M, up 5% year-over-year, significantly exceeding analyst expectations of $17.75M. However, despite this revenue growth, the company posted a loss per share of -$0.04, missing estimates and reflecting ongoing operational challenges exacerbated by restructuring efforts.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Exceeds Expectations
- Actual revenue of $21.15M surpassed estimates of $17.75M, reflecting a 5% increase year-over-year.
- Gross Margin Holds Steady
- Gross margin was reported at 53.5%, slightly down from 54.6% in the prior year.
- Significant R&D Cost Reduction
- R&D expenses dropped by 61%, from $5.44M to $2.12M, attributed to restructuring.
- Substantial Reduction in SG&A
- SG&A expenses decreased by 38%, from $29.82M to $18.61M, improving operational efficiency.
- Cash Position Strengthened
- Cash, cash equivalents, and investments increased to $526.5M from $213.3M, bolstered by the sale of the SomaScan Business.
- Positive Cash Flow from Investing Activities
- Net cash provided by investing activities was $191.1M, driven largely by the proceeds from the SomaScan divestiture.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Nasdaq Compliance Risk
- The company received a notice from Nasdaq for falling below the $1.00 minimum bid price requirement for listing.
- Negative Operating Cash Flow
- Operating activities resulted in a cash outflow of $46.6M, an increase from $30.3M year-over-year.
- Dependency on Future Capital Raises
- The company admitted that its liquidity depends significantly on maintaining revenue levels and access to funding.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.04
- Gross margin
- 53.5%
What they said about what is next.
2026 revenue guidance lowered to $70M-$75M from previous estimates of $80M-$85M.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 16, 2026
- Standard BioTools positions itself as a focused life‑science tools company concentrating on mass cytometry, spatial biology and genomics after divesting its SomaScan aptamer/proteomics business. The 10‑K documents a…
- 10-Q · November 4, 2025
- Standard BioTools reported Q3 revenue of $19.552M, down from $22.086M in Q3 2024, while GAAP net loss widened to $34.687M (EPS -$0.09). Gross margin compressed to 48.5% and operating loss widened as operating expenses…
- 10-Q · August 15, 2025
- Standard BioTools reported continuing-operations revenue of $21,762 (thousands) for Q2 2025, down from $22,492 in Q2 2024, while gross margin improved to 48.8% and operating loss narrowed. The company classified the…
- 10-K · March 11, 2025
- Standard BioTools reported a mixed performance in its latest 10-K filing for the fiscal year ending December 31, 2024. The company experienced a revenue increase, aided by key acquisitions including SomaLogic, but…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LAB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever